LEO Pharma announces changes to its Global Leadership Team
LEO Pharma today announced that Nathalie Daste, Executive Vice President of Global People & Corporate Affairs, has decided to resign her position and leave LEO Pharma due to personal reasons.
Christophe Bourdon, CEO of LEO Pharma, said: “I want to express heartfelt gratitude to Nathalie for her dedication to the journey we are currently on. In the Global Leadership Team, we will miss Nathalie, her engagement, and her fresh ideas, but I fully understand the need to put family first.”
Nathalie Daste said: “It is with mixed emotions that I share the news of my departure from this remarkable organization. Due to unforeseen family circumstances, I have made the difficult decision to step away from my role. While it is hard to bid farewell to such a talented and dedicated team, I am confident that the organization will continue to thrive and achieve great things.”
Effective immediately, Michael Meyer, currently Head of HR Business Partnering and an experienced HR leader, will step in until a permanent solution has been identified. As a result, he will also join the Global Leadership Team. Michael is recognized for his strong leadership and solid HR background from various roles and industries, with the last 12 years spent within LEO Pharma. Throughout his career, Michael has worked internationally across the entire pharma value chain and held leadership roles in Europe, North America, and Asia.
Following this change, LEO Pharma's Global Leadership Team will comprise the following executives: Christophe Bourdon, CEO, Philip Eickhoff, CFO, Sven Hauptmann, EVP, Technical Development and Supply, Brian Hilberdink, EVP, Region North America, Kreesten Meldgaard Madsen, CDO, Global Development, Michael Meyer, EVP, Global People & Corporate Affairs, Becki Morison, EVP, Global Product Strategy & International Operations, and Jacob Pontoppidan Thyssen, CSO, Research & Early Development.
Kontakter
For further information please contact:
Media: Jeppe Ilkjær, mobile: +45 30502014
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of approx. 4,200 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP)3.6.2025 09:00:00 CEST | Pressemeddelelse
The phase 2a proof-of-concept trial will recruit up to 135 adult patients with mild to severe PPP to investigate the efficacy and safety of delgocitinib cream compared to cream vehicle. Delgocitinib cream has been shown to inhibit the activity of all four JAKs,(1,2) making it a potential therapeutic candidate for treating PPP.
LEO Pharma continues to strengthen strategic leadership in medical dermatology with appointment of Helle Hedegaard Juhl as new EVP of Global People & Corporate Affairs2.6.2025 10:00:00 CEST | Pressemeddelelse
A few weeks ago, LEO Pharma announced the appointment of a new EVP for Global People & Corporate Affairs (GPCA) – Helle Hedegaard Juhl will be joining LEO Pharma on July 1. She joins LEO Pharma, alongside recently appointed EVP for International Operations Frederik Kier, to strengthen the company’s leadership and support the next phase of LEO Pharma's strategic journey and transformation
LEO Pharma delivers 9% revenue growth at constant exchange rates and doubles adjusted EBITDA margin to 16%15.5.2025 09:00:00 CEST | Pressemeddelelse
Three-month interim report (Q1) 2025 (Unaudited)
To sharpen focus on the global commercialization of strategic products and the external partnership model, LEO Pharma makes changes to leadership13.5.2025 13:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 13 May 2025 -- At LEO Pharma, we have made significant progress on our transformation journey. With our strategy on the right track, we have reached a point on our journey that requires a focus on the long term and the profiles required to shape our future. In light of this, we are announcing the following changes to our Executive Management team: We will split the current Product Strategy and International Operations into two functions, and with this EVP Becki Morison will be leaving LEO Pharma, effective end of June 2025. Frederik Kier has been appointed as EVP, International Operations and will start at LEO Pharma on June 1, 2025. Frederik joins LEO Pharma from a position as Senior Vice President, Global Obesity Unit at Novo Nordisk. Frederik’s long career at Novo Nordisk spans commercial roles, including international experience as SVP Region Northwest Europe, and SVP Region AAMEO (Africa, Asia, Middle East and Oceania). Lisa Elliott, currently Vice President, Gl
LEO Pharma announces Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe Atopic Dermatitis9.5.2025 12:00:00 CEST | Pressemeddelelse
Temtokibart achieved positive results for the primary endpoint for the 3 highest doses in a phase 2b clinical trial in adults with moderate-to-severe atopic dermatitis (AD) Temtokibart – also called LEO 138559 – is an investigational IL-22RA1 antagonist
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum